Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Clobazam (low, medium and high doses) plus ASMs leads to higher number of participants with adverse events leading to study… compared with placebo plus ASMs (high certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Felbamate plus ASMs showed no clear difference in number of participants with adverse events leading to study… compared with placebo plus ASMs (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Lamotrigine plus ASMs showed no clear difference in number of participants with adverse events leading to study… compared with placebo plus ASMs (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Rufinamide plus ASMs showed no clear difference in number of participants with adverse events leading to study… compared with placebo plus ASMs (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Cannabidiol (10 mg/kg and 20 mg/kg) plus ASMs leads to higher number of participants with adverse events leading to study… compared with placebo plus ASMs (high certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of adverse events requiring discontinuation of treatment ‐ not reported · Lennox‐Gastaut syndrome, any age
Rufinamide plus ASMs showed no clear difference in number of participants with treatment‐emergent adverse events… compared with other ASM plus ASMs (low certainty).
1 finding from 1 review